Adeno-associated virus (AAV) vectors
AAV is highlighted as a safe and promising vector for clinical-stage experimental gene therapies.
There has been a resurgence in gene therapy efforts that is partly fueled by the identification and understanding of new gene delivery vectors. Adeno-associated virus (AAV) is a non-enveloped virus that can be engineered to deliver DNA to target cells, and has attracted a significant amount of attention in the field, especially in clinical-stage experimental therapeutic strategies. The ability to generate recombinant AAV particles lacking any viral genes and containing DNA sequences of interest for various therapeutic applications has thus far proven to be one of the safest strategies for gene therapies. This review will provide an overview of some important factors to consider in the use of AAV as a vector for gene therapy.
Building similarity graph...
Analyzing shared references across papers
Loading...
Michael Naso
Brian Tomkowicz
William L. Perry
BioDrugs
Janssen (United States)
Springhouse
Cook Biotech (United States)
Building similarity graph...
Analyzing shared references across papers
Loading...
Naso et al. (Sat,) studied this question.
www.synapsesocial.com/papers/69d7429658d71cbec648f5b1 — DOI: https://doi.org/10.1007/s40259-017-0234-5